Table 3. Univariate and multivariate Cox regression analyses of patient and tumour factors with DFS and OS in Stage III-IVa patients.
P value | DFS | P value | OS | |
---|---|---|---|---|
HR (95% CI) | HR (95% CI) | |||
Univariate analysis | ||||
sTIL (>10%) | 0.031 | 0.615 (0.395–0.957) | 0.007 | 0.544 (0.349–0.850) |
iTIL (>10%) | 0.620 | 0.895 (0.577–1.389) | 0.557 | 0.875 (0.561–1.366) |
iTIL (>20%) | 0.046 | 0.309 (0.097–0.980) | 0.061 | 0.331 (0.104–1.052) |
sCD4 (>10%) | 0.521 | 0.787 (0.379–1.635) | 0.399 | 0.730 (0.351–1.518) |
sCD8 (>10%) | 0.078 | 0.654 (0.408–1.048) | 0.036 | 0.599 (0.371–0.968) |
iCD8 (>10%) | 0.329 | 0.780 (0.474–1.284) | 0.314 | 0.767 (0.458–1.285) |
sFoxp3 (>10%) | 0.182 | 0.260 (0.036–1.878) | 0.160 | 0.241 (0.033–1.749) |
Sex | 0.336 | 0.710 (0.354–1.425) | 0.449 | 0.868 (0.600–1.254) |
Age | 0.409 | 1.202 (0.777–1.859) | 0.340 | 1.238 (0.799–1.919) |
Grade | 0.922 | 0.980 (0.658–1.461) | 0.804 | 0.950 (0.633–1.426) |
Vessel invasion | 0.596 | 1.128 (0.723–1.760) | 0.366 | 1.230 (0.786–1.925) |
Nerve invasion | 0.322 | 1.249 (0.804–1.939) | 0.245 | 1.300 (0.836–2.021) |
Lymph node metastasis | 0.101 | 0.521 (0.239–1.137) | 0.208 | 0.606 (0.278–1.321) |
Site | 0.011 | 0.620 (0.429–0.896) | 0.013 | 0.622 (0.427–0.905) |
Smoking | 0.295 | 0.792 (0.513–1.224) | 0.296 | 0.791 (0.510–1.228) |
Multivariate analysis | ||||
sTIL (>10%) | 0.081 | 0.671 (0.428–1.051) | 0.032 | 0.535 (0.303–0.947) |
iTIL (>20%) | 0.056 | 0.322 (0.101–1.028) | 0.071 | 0.341 (0.106–1.095) |
sCD8 (>10%) | 0.785 | 1.091 (0.584–2.040) | ||
Site | 0.038 | 0.032 | ||
Middle | 0.233 | 0.557 (0.213–1.457) | 0.144 | 0.479 (0.178–1.285) |
Lower | 0.036 | 0.359 (0.138–0.934) | 0.022 | 0.311 (0.114–0.848) |
DFS, disease free survival. OS, disease specific overall survival. HR, hazard ratio. CI, confidence interval. sTIL, stromal infiltrating lymphocytes. iTIL, intratumoural infiltrating lymphocytes. sCD4, CD4+ stromal infiltrating lymphocytes. sCD8, CD8+ stromal infiltrating lymphocytes. iCD8, CD8+ intratumoural infiltrating lymphocytes. sFoxp3, Foxp3+ stromal infiltrating lymphocytes. iFoxp3, Foxp3+ intratumoural infiltrating lymphocytes.